SHANGHAI, China, FOSTER CITY, CA, and July 28th, 2020 – Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”; 3692:HK) and Terns Pharmaceuticals, Inc., today announced a collaboration and license agreement for the development and commercialization of TRN-000632, an investigational small molecule allosteric inhibitor of BCR-ABL for the treatment of chronic myeloid leukemia (CML), in Greater China.
Under the terms of the agreement, Hansoh will receive the exclusive rights to develop and commercialize TRN-000632 in Greater China. Terns will receive an upfront payment and will be eligible to receive development, regulatory and commercial milestones of up to $68 million, as well as royalties from future product sales.
For more information about the collaboration, please refer to
About Hansoh Pharmaceutical Group Company Limited
Hansoh Pharma (3692.HK), a leading biopharmaceutical company in Asia, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Hansoh Pharma is supported by over 9,000 dedicated employees in China and the United States.
Founded in 1995, Hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting leading positions in oncology, central nervous system (CNS) disorders, infectious diseases, gastrointestinal disorders, diabetes, and autoimmune diseases, among others in China. With over 1,200 professionals across R&D, Hansoh has successfully developed multiple internally discovered drug candidates into NMPA-approved innovative medicines including morinidazole (迈灵达), a third-generation nitroimidazole antibiotic; PEG-loxenatide (孚来美), the first once-weekly long-acting GLP-1 analogue discovered and developed in China for the treatment of diabetes; flumatinib (昕福), a second-generation BCR-ABL inhibitor for frontline treatment of chronic myeloid leukemia (CML); and almonertinib (阿美乐), a third-generation EGFR inhibitor for the treatment of NSCLC with EGFR mutations.
For more information, please visit www.hspharm.com
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn
CONTACT
Hansoh Pharma
Global Business Development
Paul Lu
partner@hansohbio.com
Investor Relations
Sophia Dong
dongss1@hspharm.com
Terns Pharmaceuticals, Inc.
US Media Contact:
Margaret Robinson
mrobinson@ternspharma.com
+1 (415) 690 0084
China Media Contact:
Zhou Zhou
zzhou@ternspharma.com
